Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...
Pfizer Inc. today announced detailed results from the pivotal Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® ...
The show of hands at this year's ASCO annual meeting is unmistakable. BioNTech is presenting more than 25 clinical studies in Chicago, including 13 pivotal trials — an extraordinary concentration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results